Day: November 3, 2023

Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to December 3, 2023

Written by Customer Service on November 3, 2023. Posted in Mergers And Acquisitions.

MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) — Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced that on November 2, 2023, its sponsor, Vision Sensing, LLC, deposited $60,000 into the Company’s trust account, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from November 3, 2023, to December 3, 2023 (the “Extension”). The Company has issued to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $60,000 as consideration for the funding. This is the first of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on October 25, 2023. The Extension provides...

Constellation Brands Announces Expiration of Canopy Growth Warrants

Written by Customer Service on November 3, 2023. Posted in Public Companies.

VICTOR, N.Y., Nov. 03, 2023 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today the expiration of all its warrants (“Warrants”) to purchase common shares (“Common Shares”) of Canopy Growth Corporation (“Canopy”). All 88,472,861 Tranche A warrants held by Constellation’s wholly-owned subsidiary, CBG Holdings LLC (“CBG”), expired as of November 1, 2023. Since the vesting of the remaining aggregate of 51,272,592 Tranche B and Tranche C warrants was conditioned on the exercise, in full, of the Tranche A warrants, the remaining Warrants are not, and will not become, exercisable by CBG. As a result, Constellation is no longer deemed to beneficially own any of the 139,745,453 Common Shares underlying the Warrants. The 139,745,453 Common Shares underlying the Warrants would have...

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

Written by Customer Service on November 3, 2023. Posted in Public Companies.

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vaccine, as monotherapy, 87% (20/23) had direct ex vivo mKRAS-specific T cell responses, and 100% (23/23) had in vitro stimulated responses. The strength of the induced T cell response correlated with a significantly reduced risk of relapse and death.Among the four patients assessed for durability of immune response post-boost immunizations with ELI-002, 100% maintained elevated T cell responses above baseline, with 75% producing an increased response post-boost.ELI-007, an investigational mutant BRAF-peptide vaccine, and ELI-008, an investigational p53 hotspot mutation-peptide vaccine, demonstrated strong induction of tumor-antigen-specific T cell responses in mice, increased >10-500-fold...

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Written by Customer Service on November 3, 2023. Posted in Earnings Releases And Operating Results.

— Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems — — Shared detailed safety evaluation of lead Prime Editors across multiple programs; preliminary off-target analyses did not identify off-target editing, supporting potential best-in-class safety profile — — Received U.S. FDA Rare Pediatric Drug designation for PM359 for CGD; initiated IND-enabling studies and remain on track to file IND application in 2024 — — Further extended intellectual property portfolio; U.S. PTO issued Prime Medicine’s third patent, No. 11,795,452 — CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed...

Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Written by Customer Service on November 3, 2023. Posted in Earnings Releases And Operating Results.

Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in combination with pembrolizumab in patients with advanced solid tumors Initial KVA12123 monotherapy clinical safety, pharmacokinetic, receptor occupancy and biomarker data to be presented at SITC 2023 Expected Cash Runway into early 2025 SEATTLE, Nov. 03, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update. “We are thrilled to share the significant progress made during the third quarter of 2023, highlighted by announcing, in September, initial...

Senvest Capital Inc. Reports Results for the Third Quarter Ended September 30, 2023

Written by Customer Service on November 3, 2023. Posted in Earnings Releases And Operating Results.

MONTREAL, Nov. 03, 2023 (GLOBE NEWSWIRE) — Senvest Capital Inc. today reported net loss attributable to common shareholders of ($67.0) million or ($27.07) per share for the three months ended September 30, 2023. This compares to a net loss attributable to common shareholders of ($118.5) million or ($47.72) per share for the same period in 2022. For the nine months ended September 30, 2023, the net loss attributable to common shareholders was ($2.1) million or ($0.83) per share compared to a net loss attributable to common shareholders of ($479.9) million or (192.56) per share the prior year. Financial statements are available online at Sedar www.sedar.com CONSOLIDATED STATEMENT OF LOSS (unaudited) (in millions of dollars, except per share amounts) For the three months ended For the nine months ended 09/30/2023 09/30/2022 09/30/2023 09/30/2022 Net...

Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Written by Customer Service on November 3, 2023. Posted in Public Companies.

Lead Anti-CD27 Monoclonal Antibody Showed High Binding Affinity and Specificity Drives Strong T Cell Activation and Proliferation as well as NK Cell Activation Demonstrated In Vivo Antitumor Efficacy as a Single Agent and in Combination with Checkpoint Inhibitors in Solid and Hematological Tumor Models SEATTLE, Nov. 03, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the presentation of new preclinical data on the company’s anti-CD27 agonist monoclonal antibodies (mAbs) at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, presented the company’s poster revealing new preclinical data. “We...

Kaixin Auto Holdings Announces Unaudited First Half 2023 Financial Results

Written by Customer Service on November 3, 2023. Posted in Public Companies.

BEIJING, Nov. 03, 2023 (GLOBE NEWSWIRE) — Kaixin Auto Holdings (“Kaixin” or the “Company”) (NASDAQ: KXIN), a leading new energy vehicle manufacturer and one of the premium imported cars and used cars platform in China, today announced its unaudited financial results for the six months ended June 30, 2023. First Half of 2023 HighlightsTotal net revenues were US$18.9 million, representing a decrease of 43% from US$33.3 million in the first half of 2022.Gross profit was US$0.2 million, keeping stable with that of US$0.2 million in the first half of 2022.Loss from operations was US$4.1 million, substantially less than the loss from operations of US$32.8 million in the first half of 2022Net loss attributable to the Company was US$4.5 million, substantially improved over the net loss attributable to the Company of US$70.6 million...

UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Written by Customer Service on November 3, 2023. Posted in Mergers And Acquisitions.

Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fund operations into 2026 Funds multiple potentially value-creating milestones, including advancing its lead product candidate in Alpha-1 antitrypsin deficiency (AATD) through a clinical trial Shares to trade on Nasdaq under the ticker “KRRO” commencing on November 6, 2023CAMBRIDGE, Mass. and LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both rare and highly prevalent diseases, today announced the completion of the previously announced business combination between Frequency Therapeutics,...

Fluent, Inc. to Announce Third Quarter Financial Results on November 14, 2023

Written by Customer Service on November 3, 2023. Posted in Public Companies.

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT) announced today that it will report its financial results for the Third Quarter 2023 after the close of the U.S. financial markets on November 14, 2023. Fluent will host a conference call at 4:30 pm ET on the same day to discuss the results. The conference call can be accessed by phone after registering online at Fluent Conference Call or via audio at Audio Registration. The call will also be webcast simultaneously on the Fluent website on the Investor Relations Page. Please log in at least 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be required. Following the call, a recorded replay of the webcast will be available for one year on Fluent’s Investor Relations Page. About Fluent, Inc. Fluent is a leading performance...

Day: November 3, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice